Daily Newspaper

AstraZeneca ten Phase 3 trial chhunzawm

9

Pharma giant AstraZeneca te chuan Covid-19 vaccine trial chu volunteer pakhat damloh avanga an chawlhsan hnua British regulator tena remtihna an pek leh tak hnuah an chhunzawm leh tak thu an sawi.

“AstraZeneca Oxford coronavirus vacccine, AZD1222 chu UK ah Medicines Health Regulatory Authority (MHRA) tena a him tia remtihna an pek hnuah chhunzawm a ni,” tiin company te chuan thuchhuah siamin an tarlang.

Kar kalta Nilaini khan AastraZeneca te chuan Oxford University te nena vaccine an siam chu volunteer pakhat a chhan hriatloha a dam loh tak vak avangin an lo chawlhsan tawh a ni.

Review safety nei turin independent committee din zui nghal niin hei hi company leh World Health Organization te chuan tihdan phung pangngai tiin an sawi.

Committee chuan investigation an neih hnuah UK-ah MHRA trial chu neih chhunzawm an remti tiin AstraZeneca te chuan an sawi a.

AstraZeneca te vaccine siam mek hi khawvel puma Phase 3 human trial kalpui mek vaccine pakua zinga tel a ni.

United States of America-ah chuan he vaccine hi volunteer 30,000 te lakah Augusut 31 atang khan enchinna neih mek niin hei bakah hian Brazil leh South America-ah te pawh enchhin a ni bawk a.

AZD1222 vaccine hian hritlang satliah thlentu adenovir chu siam danglamin Covid-19 cell te runtu laka a him theih nana protein tisang turin hna a thawk a ni.

Vaccine pek a nih hnuah he protein hi mihring taksaah chambangin a insiam thei a, chu chu coronavirus laka mihring venghimtu turin a thawk thei tura ngaih a ni.

(THE AIZAWL POST – Ramchhung)

The Aizawk Post

Full>> ePaper Subscribe

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy